Cellectis SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010425595
EUR
4.11
-0.46 (-10.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

590.41 k

Shareholding (Jun 2018)

FII

0.03%

Held by 1 FIIs

DII

99.97%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 131.68%, its profits have risen by 50.5%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 294 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

-33.59%

stock-summary
Price to Book

3.44

Revenue and Profits:
Net Sales:
15 Million
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.07%
0%
53.07%
6 Months
221.6%
0%
221.6%
1 Year
131.68%
0%
131.68%
2 Years
56.99%
0%
56.99%
3 Years
85.64%
0%
85.64%
4 Years
-47.04%
0%
-47.04%
5 Years
-84.04%
0%
-84.04%

Cellectis SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
3.10%
EBIT Growth (5y)
10.04%
EBIT to Interest (avg)
-8.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.45
Sales to Capital Employed (avg)
0.14
Tax Ratio
8.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.38
EV to EBIT
-3.67
EV to EBITDA
-5.95
EV to Capital Employed
-10.87
EV to Sales
3.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-63.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2018stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 45.54% vs -15.13% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -21.51% vs -407.14% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.70",
          "val2": "10.10",
          "chgp": "45.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-10.50",
          "chgp": "45.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "1.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "1.80",
          "chgp": "-111.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.90",
          "val2": "-17.20",
          "chgp": "-21.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-683.60%",
          "val2": "-1,499.70%",
          "chgp": "81.61%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5,385.71% vs -96.15% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.55% vs -15.12% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "38.40",
          "val2": "0.70",
          "chgp": "5,385.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.60",
          "val2": "-81.50",
          "chgp": "45.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.90",
          "val2": "5.90",
          "chgp": "16.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.80",
          "val2": "-19.00",
          "chgp": "156.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.00",
          "val2": "-108.10",
          "chgp": "68.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,641.20%",
          "val2": "-141,226.50%",
          "chgp": "13,958.53%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
14.70
10.10
45.54%
Operating Profit (PBDIT) excl Other Income
-5.70
-10.50
45.71%
Interest
1.80
1.80
Exceptional Items
-0.20
1.80
-111.11%
Consolidate Net Profit
-20.90
-17.20
-21.51%
Operating Profit Margin (Excl OI)
-683.60%
-1,499.70%
81.61%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 45.54% vs -15.13% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -21.51% vs -407.14% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
38.40
0.70
5,385.71%
Operating Profit (PBDIT) excl Other Income
-44.60
-81.50
45.28%
Interest
6.90
5.90
16.95%
Exceptional Items
10.80
-19.00
156.84%
Consolidate Net Profit
-34.00
-108.10
68.55%
Operating Profit Margin (Excl OI)
-1,641.20%
-141,226.50%
13,958.53%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5,385.71% vs -96.15% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.55% vs -15.12% in Dec 2023

stock-summaryCompany CV
About Cellectis SA stock-summary
stock-summary
Cellectis SA
Pharmaceuticals & Biotechnology
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Company Coordinates stock-summary
Company Details
8, rue de la Croix Jarry , PARIS None : 75013
stock-summary
Tel: 33 1 816916001 646 3859008
stock-summary
Registrar Details